← Leaderboards
Terzah M Horton
Baylor College Of Medicine
$4,270,013
Attributed
$8,351,529
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,351,529 · 5
By mechanism
R01$7,158,654 · 2
K23$670,075 · 1
P20$522,800 · 2
Top collaborators
- Michelle L Hermiston8 shared
- David T. Teachey8 shared
- Brent L Wood8 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Cliona M Rooney$13,445,584
- Michele S. Redell$3,028,784
- Grzegorz A. Ira$8,919,160
- Malcolm K Brenner$13,204,649
- David John Tweardy$14,168,425
Others in their field
Top investigators on “Biology”
- David Heimbrook · Leidos Biomedical Research, Inc.$731,505,112
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Lawrence Corey · Fred Hutchinson Cancer Center$543,202,300
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$480,487,534
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
BiologySamplingRelapseBortezomibPathway InteractionsProteasome InhibitorChemotherapyChildCellsClinical TrialsMolecular ProfilingBasePediatric Oncology GroupProtein ExpressionDisease-Free SurvivalResponseProteinsPhase Iii Clinical TrialsAdultLeukemia/LymphomaEffectivenessApoptosisMediatingLead
Grant awards (22)
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$737,926
R01 · FY2025 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$721,069
R01 · FY2024 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$851,561
R01 · FY2023 · CA
Biospecimen Processing and Storage Core$164,367
P20 · FY2023 · CA · contact PI
Biospecimen Processing and Storage Core$171,289
P20 · FY2022 · CA · contact PI
Biospecimen Processing and Storage Core$187,144
P20 · FY2021 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$575,456
R01 · FY2019 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$594,741
R01 · FY2018 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$625,779
R01 · FY2017 · CA
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML$319,474
R01 · FY2017 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$626,176
R01 · FY2016 · CA
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML$309,159
R01 · FY2016 · CA · contact PI
Improving risk allocation and developing novel therapies for children with T-ALL$709,314
R01 · FY2015 · CA
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML$376,095
R01 · FY2015 · CA · contact PI
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML$322,104
R01 · FY2014 · CA · contact PI
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML$3,941
R01 · FY2014 · CA · contact PI
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML$385,859
R01 · FY2013 · CA · contact PI
Proteosome Inhibition Therapy for Hematologic Malignancy$134,015
K23 · FY2010 · CA · contact PI
Proteosome Inhibition Therapy for Hematologic Malignancy$134,015
K23 · FY2009 · CA · contact PI
Proteosome Inhibition Therapy for Hematologic Malignancy$134,015
K23 · FY2008 · CA · contact PI
Proteosome Inhibition Therapy for Hematologic Malignancy$134,015
K23 · FY2007 · CA · contact PI
Proteosome Inhibition Therapy for Hematologic Malignancy$134,015
K23 · FY2006 · CA · contact PI